Biologic Specimen and Data Repository Information Coordinating Center
Home > Proprietary Studies > TOPCAT

Resources Available

Specimens Only

Materials Available

Packed Cells
Plasma
Serum
Urine
Whole Blood

Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist (TOPCAT)

Website: http://www.topcatstudy.com/
Parent Study Contact: Akshay Desai, adesai@partners.org
Study Type: Clinical Trial
Prepared on August 4, 2011
Consent: Restricted Consent
Consent Restrictions: For protocol use only
Commercial Use Restrictions: No
Collection Type: Proprietary Study - See bottom of this webpage for request information

Objectives

TOPCAT is a multi-center, international, randomized, double blind placebo-controlled trial of the aldosterone antagonist spironolactone, in 3515 adults with heart failure and left ventricular ejection fraction of at least 45%, recruited from over 200 clinical centers. The primary endpoint is a composite of cardiovascular mortality, aborted cardiac arrest or hospitalization for the management of heart failure. Secondary endpoints include all-cause mortality, new onset of diabetes mellitus or atrial fibrillation, and quality of life.


Interested parties should review the Proprietary Study application process before they begin. Requests for Proprietary Studies must be approved by the Parent Study before they can be processed by BioLINCC. Contact information for the Parent Study is provided at the top of this webpage. Upon Parent Study approval, click the Request button to start a request through BioLINCC.